论文部分内容阅读
AIM:To explain the role of Monocyte chemotactic protein-1(MCP-1) and soluble adhesion molecules in chronic hepatitisC during the treatment of interferon alpha (IFNα) 2 b andribavirin (RBV).METHODS:Concentrations of MCP-1,soluble adhesionmolecules intercellular adhesion molecule-1 (sICAM-1),sP-selectin,interleukin (IL) 6,and IL10 in serum were estimatedin the group of 40 patients with chronic hepatitis C treatedwith IFNalpha2 b and RBV in 0,16,32,48 wk of the therapy,RESULTS:In chronic hepatitis C,before and during thetreatment,the serum levels of MCP-1 and sP-selectin inresponders were similar to those of healthy subjects.In non-responders (NR),MCP-1 increased in the course of IFNc~+RBVtreatment,differences were statistically significant ascompared to responders.MCP-1 correlated statistically withthe activity of periportal inflammation (r=0.35,P<0.05) butnot with staging of liver fibrosis,sICAM-1 positively correlatedwith inflammatory activity and fibrosis in NR.sP-selectin didnot correlate with histological findings in the liver.TheMCP-1 correlated with the soluble form of sP-selectinconcentrations (r= 6,P<0.001) and with IL-10 level in NR(r=0.4,P<0.05).There was no correlation observedbetween the concentration of MCP-1 and sICAM-1,IL-6during the treatment.CONCLUSION:MCP-1 concentration may be a prognosticmarker of the efficacy of IFN+RBV therapy in patients withchronic hepatitis C.
AIM: To explain the role of Monocyte chemotactic protein-1 (MCP-1) and soluble adhesion molecules in chronic hepatitis C during the treatment of interferon alpha (IFNα) 2 b and ribavirin (RBV) .METHODS: Concentrations of MCP-1, soluble adhesion molecules Intercellular adhesion molecule-1 (sICAM-1), sP-selectin, interleukin (IL) 6, and IL10 in serum were estimated in the group of 40 patients with chronic hepatitis C treated with IFNalpha 2b and RBV in 0,16,32,48 wk of the therapy, RESULTS: In chronic hepatitis C, before and during the treatment, the serum levels of MCP-1 and sP-selectin inresponders were similar to those of healthy subjects. In non-responders (NR), MCP-1 increased in the course of IFNc ~ + RBVtreatment, the differences were statistically significant as compared to responders. MCP-1 correlated statistically with the activity of periportal inflammation (r = 0.35, P <0.05) butnot with staging of liver fibrosis, sICAM-1 positively correlated with inflammatory activity and fibrosis in NR.sP-selectin didnot cor relate with histological findings in the liver. MCP-1 correlated with the soluble form of sP-selectin concentrations (r = 6, P <0.001) and with IL-10 level in NR correlation observed between the concentration of MCP-1 and sICAM-1, IL-6during the treatment. CONCLUSION: MCP-1 concentration may be a prognostic marker of the efficacy of IFN + RBV therapy in patients with chronic hepatitis C.